Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Liabilities and Shareholders Equity (2019 - 2025)

Historic Liabilities and Shareholders Equity for Korro Bio (KRRO) over the last 7 years, with Q3 2025 value amounting to $161.5 million.

  • Korro Bio's Liabilities and Shareholders Equity fell 3366.67% to $161.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $770.4 million, marking a year-over-year decrease of 1559.6%. This contributed to the annual value of $226.2 million for FY2024, which is 206.48% up from last year.
  • As of Q3 2025, Korro Bio's Liabilities and Shareholders Equity stood at $161.5 million, which was down 3366.67% from $180.4 million recorded in Q2 2025.
  • Korro Bio's 5-year Liabilities and Shareholders Equity high stood at $249.6 million for Q2 2024, and its period low was $46.3 million during Q3 2023.
  • In the last 5 years, Korro Bio's Liabilities and Shareholders Equity had a median value of $185.4 million in 2021 and averaged $172.8 million.
  • In the last 5 years, Korro Bio's Liabilities and Shareholders Equity plummeted by 6592.31% in 2023 and then skyrocketed by 42545.47% in 2024.
  • Korro Bio's Liabilities and Shareholders Equity (Quarter) stood at $185.4 million in 2021, then crashed by 60.22% to $73.7 million in 2022, then surged by 200.59% to $221.7 million in 2023, then increased by 2.06% to $226.2 million in 2024, then dropped by 28.59% to $161.5 million in 2025.
  • Its Liabilities and Shareholders Equity was $161.5 million in Q3 2025, compared to $180.4 million in Q2 2025 and $202.2 million in Q1 2025.